New Low-Light Level Therapy Shows Promising Results for CCCA

REVIAN Inc. revealed positive outcomes for the use of REVIAN Red System to treat patients with Central Centrifugal Cicatricial Alopecia (CCCA).1 Researchers at Wake Forest University School of Medicine in Salem-West, North Carolina, presented their findings regarding CCCA and the REVIAN Red System at the virtual 2021 Society for Investigative Dermatology annual meeting.

Your cart

Your cart is empty

Uh oh! Your cart is empty.

Continue shopping